Abstract
Endothelial dysfunction is considered one of the main mechanisms for the further development of arterial hypertension (AH) and its complications, and endothelin-1 (ЕТ-1) plays one of the key roles in this process. Endothelium is drawn into the pathological process at the earliest stages of AH development. ЕТ-1 is currently considered as a marker and predictor of the stage and consequences of AH, chronic heart failure (CHF), coronary heart disease (CHD), in particularly, acute myocardial infarction (MI), heart rhythm disorders, pulmonary hypertension, atherosclerotic vascular injury, target vascular disorders. One factor that may influence the level of ЕТ-1 is the endothelin-1 gene Lys198Asn polymorphism, which is considered by many researchers as a possible genetic marker of AH. However, the effect of this polymorphism on the level of plasma ЕТ-1 level in patients with AH of varying severity in Ukraine is understudied. The basis of this work were the materials of a complete examination of 160 patients with a verified diagnosis of AH I, stage II of 1, 2, 3 degrees (main group) and 110 apparently healthy persons (control group). Patients of the main group were divided into three subgroups: 1st group – 75 patients with normal body weight; 2nd group – 48 overweight patients; 3rd group – 37 patients with alimentary obesity. In obese patients, the waist circumference in women was around 103 (96–115) cm, and in men – 108 (105–116) cm, which indicates an abdominal type of obesity in these patients. As a result of the study, it was found that the level of ЕТ-1 is higher in patients with AH who suffer with overweight and obesity as compared with patients with AH and normal body weight. Also, the peptide level depends on the genotype of patients and is higher in AH patients with the genotype Asn198Asn and Lys198Asn as compared to carriers of the genotype Lys198Lys.
Highlights
PLASMA CONCENTRATION OF ENDOTHELIN-1 IN PATIENTS WITH HYPERTENSION ASSOCIATED WITH OBESITY, DEPENDING ON THE LYS198ASN POLYMORPHISM OF THE ENDOTHELIN-1 GENE
ЕТ-1 is currently considered as a marker and predictor of the stage and consequences of arterial hypertension (AH), chronic heart failure (CHF), coronary heart disease (CHD), in acute myocardial infarction (MI), heart rhythm disorders, pulmonary hypertension, atherosclerotic vascular injury, target vascular disorders
One factor that may influence the level of ЕТ-1 is the endothelin-1 gene Lys198Asn polymorphism, which is considered by many researchers as a possible genetic marker of AH
Summary
Рівень ЕТ-1 є однаковим у хворих на АГ з різними стадіями (р = 0,072). Таблиця 2 – Плазмова концентрація ендотеліну-1 у хворих на артеріальну гіпертензію з різним індексом маси тіла залежно від ступеня артеріальної гіпертензії, фмоль/мл (M ±m). Проаналізувавши отримані дані можна зробити висновок, що рівень ЕТ-1 вищий у пацієнтів хворих на АГ з надлишковою масою тіла та ожирінням, порівняно з хворими на АГ з нормальною масою тіла. Концентрація пептиду підвищується залежно від ступеня АГ і є найвищою у хворих з 3 ступенем АГ. Рівень пептиду залежить від генотипу пацієнтів і є вищим у хворих на АГ з генотипом Asn198Asn та Lys198Asn порівняно з носіями генотипу Lys198Lys. Отримані результати вказують на те, що визначаючи рівень ЕТ-1 у хворих на АГ та враховуючи їхній генотип за Lys198Asn поліморфізмом гена ЕТ-1, можна прогнозувати тяжкість АГ поєднаної з ожирінням
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call